Free Trial

Carmell (NASDAQ:CTCX) Trading Down 2.8% - What's Next?

Carmell logo with Medical background

Carmell Co. (NASDAQ:CTCX - Get Free Report)'s share price fell 2.8% during mid-day trading on Thursday . The stock traded as low as $2.38 and last traded at $2.45. 18,767 shares were traded during trading, a decline of 100% from the average session volume of 4,290,529 shares. The stock had previously closed at $2.52.

Carmell Trading Up 0.8%

The firm's fifty day moving average is $2.14 and its 200-day moving average is $0.93.

Institutional Investors Weigh In On Carmell

An institutional investor recently bought a new position in Carmell stock. Citadel Advisors LLC bought a new position in shares of Carmell Co. (NASDAQ:CTCX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 187,565 shares of the company's stock, valued at approximately $54,000. Citadel Advisors LLC owned about 0.90% of Carmell at the end of the most recent reporting period. 24.22% of the stock is owned by institutional investors and hedge funds.

Carmell Company Profile

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

Read More

Should You Invest $1,000 in Carmell Right Now?

Before you consider Carmell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carmell wasn't on the list.

While Carmell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines